Pharmaxis releases positive results of Phase 1 clinical trial for second LOXL2 inhibitor compound

LONDON, 15 November 2018 -- Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, is pleased to note that Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis, has announced positive results from the Phase 1 clinical trial for the second of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF).

Arix led the A$24 million (£13.4 million) financing for Pharmaxis in August, acquiring an 11.1% equity stake. Arix’s Ed Rayner joined the Pharmaxis Board of Directors in September 2018.

The announcement can be accessed on Pharmaxis’ website at http://www.pharmaxis.com.au/investor-centre/news/ and full text of the announcement from Pharmaxis is contained below.

Pharmaxis will host an investor research briefing on Tuesday, 20 November from 10am to 12.00pm (AEDT). The event will provide an overview of the Pharmaxis drug discovery pipeline including the anti-inflammatory drug currently being developed by Boehringer Ingelheim, work in collaboration with the Garvan Institute of Medical Research on an anti-fibrotic LOX inhibitor targeting pancreatic cancer and the anti-fibrotic LOXL2 inhibitor program currently completing phase 1 trials and extended toxicity studies.

This is a unique opportunity to hear directly from the Pharmaxis executive research team along with the perspectives of a committed pharmaceutical partner and a leading medical research institute. A live webcast will be accessible to all investors via the homepage of the Pharmaxis website at www.pharmaxis.com.au and will be available for replay after the event.

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com  

Optimum Strategic Communications

Mary Clark, Supriya Mathur

+44 (0)203 714 1787

optimum.arix@optimumcomms.com

Burns McClellan (US Media & IR Enquiries)

Lisa Burns, Nancie Steinberg

+1 212-213-0006

arix@burnsmc.com

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com

Back to news